{
    "ticker": "VTVT",
    "name": "VTV Therapeutics Inc.",
    "description": "VTV Therapeutics Inc. is a biotechnology company focused on the discovery and development of innovative therapies for chronic diseases. Founded in 2013, the company is based in Winston-Salem, North Carolina. VTV Therapeutics is dedicated to advancing treatments that address unmet medical needs, particularly in the areas of metabolic diseases, neurological disorders, and cancer. The company's lead product candidates include VTV-340, aimed at treating type 2 diabetes, and various other compounds in preclinical and clinical development stages. VTV Therapeutics employs a unique drug development approach that combines insights from academic research with proprietary technology platforms to create novel therapeutic solutions. The firm collaborates with major pharmaceutical companies and academic institutions to leverage expertise and resources in the pursuit of effective treatments. VTV Therapeutics is committed to improving patient outcomes through innovation and scientific advancement, making significant strides in the biotechnology field.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Winston-Salem, North Carolina, USA",
    "founded": "2013",
    "website": "https://www.vtvtherapeutics.com",
    "ceo": "John E. McKinley",
    "social_media": {
        "twitter": "https://twitter.com/vtvtherapeutics",
        "linkedin": "https://www.linkedin.com/company/vtvtherapeutics/"
    },
    "investor_relations": "https://www.vtvtherapeutics.com/investor-relations",
    "key_executives": [
        {
            "name": "John E. McKinley",
            "position": "CEO"
        },
        {
            "name": "Michael E. Hennessey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "VTV-340",
                "Various Metabolic and Neurological Candidates"
            ]
        }
    ],
    "seo": {
        "meta_title": "VTV Therapeutics Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore VTV Therapeutics Inc., a biotechnology company dedicated to developing innovative therapies for chronic diseases, focusing on metabolic and neurological disorders.",
        "keywords": [
            "VTV Therapeutics",
            "Biotechnology",
            "Chronic Diseases",
            "Pharmaceuticals",
            "Type 2 Diabetes",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What does VTV Therapeutics specialize in?",
            "answer": "VTV Therapeutics specializes in the discovery and development of innovative therapies for chronic diseases."
        },
        {
            "question": "Who is the CEO of VTV Therapeutics?",
            "answer": "John E. McKinley is the CEO of VTV Therapeutics Inc."
        },
        {
            "question": "Where is VTV Therapeutics headquartered?",
            "answer": "VTV Therapeutics is headquartered in Winston-Salem, North Carolina, USA."
        },
        {
            "question": "What are VTV Therapeutics' main product candidates?",
            "answer": "VTV Therapeutics' main product candidates include VTV-340 for type 2 diabetes and other metabolic and neurological compounds."
        },
        {
            "question": "When was VTV Therapeutics founded?",
            "answer": "VTV Therapeutics was founded in 2013."
        }
    ],
    "competitors": [
        "AMGN",
        "VRTX",
        "REGN",
        "BIIB"
    ],
    "related_stocks": [
        "GILD",
        "CELG",
        "ABBV",
        "MRNA"
    ]
}